# 2025-16271: FDA Sets VORANIGO's Patent Extension Clock Ticking

2025-16271, Determination of Regulatory Review Period for Purposes of Patent Extension; VORANIGO, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-26 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-16271
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16271
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; VORANIGO
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 41583
- Published: 2025-08-26
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Sets VORANIGO's Patent Extension Clock Ticking

## Summary

The FDA has officially set the review period for VORANIGO, a human drug product, so its patent can be extended. This means the company behind VORANIGO gets extra time to protect their invention, helping them make money while keeping the drug available. If you’re involved in drug patents or development, this update is a key step in the process.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VORANIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

## Effects PRIA read

- VORANIGO Patent Extension Eligibility: benefit, medium. The FDA has determined the regulatory review period for VORANIGO so the company may seek an extension of a patent that claims this human drug product. This gives the company extra time to protect its invention, which can help the company earn more while keeping the drug available.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-16271 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/26/2025-16271/determination-of-regulatory-review-period-for-purposes-of-patent-extension-voranigo)
- [2025-16271 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-26/pdf/2025-16271.pdf)

## Related
- [Previous: 2025-16270, Determination of Regulatory Review Period for Purposes of Patent Extension; ZUN…](https://policyrisk.com/federal-register/2025-16270)
- [Next: 2025-16272, Determination of Regulatory Review Period for Purposes of Patent Extension; OHT…](https://policyrisk.com/federal-register/2025-16272)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16271 (as of 2026-06-08).
